Video
Dr. Sultan Haider encourages physicians to examine all types of parameters in patients with hypogonadism
Author(s):
“Always look at the patient as…a whole and not only [their] testosterone levels,” says Karim Sultan Haider, MD.
Video Player is loading.
In this video, Karim Sultan Haider, MD, discusses the takeaways of the study, “Long-term Testosterone Therapy Improves Erectile Function and Reduces Mortality in Men with Hypogonadism and Type 2 Diabetes – Updated Results from a Registry Study,” presented recently at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting. Sultan Haider is an andrology and urology resident at Gesundheit Nord, Bremen, Germany.
Related Videos
FDA testosterone labeling changes: How will they affect prescribing?
Landon Trost, MD, on the impact of the FDA labeling changes for testosterone products
How urologists can discuss testosterone labeling changes with patients
John P. Mulhall, MD, shares his reaction to the FDA’s testosterone labeling changes
An expert shares their approach to testosterone therapy in men with hypogonadism
Helen L. Bernie, DO, MPH, on the FDA’s labeling changes for testosterone products
Gopa Iyer, MD, highlights findings from FORAGER-1 in metastatic urothelial carcinoma
Michael Schweizer, MD, shares data on mevrometostat plus enzalutamide in mCRPC
Laura Bukavina, MD, highlights study of urinary microbiome profiling
Kate Gessner, MD, on the mechanisms of immunotherapy failure in RCC
Related Content
